PT - JOURNAL ARTICLE AU - Bronte, Vincenzo AU - Ugel, Stefano AU - Tinazzi, Elisa AU - Vella, Antonio AU - De Sanctis, Francesco AU - Canè, Stefania AU - Batani, Veronica AU - Trovato, Rosalinda AU - Fiore, Alessandra AU - Petrova, Varvara AU - Hofer, Francesca AU - Barouni, Roza Maria AU - Musiu, Chiara AU - Caligola, Simone AU - Pinton, Laura AU - Torroni, Lorena AU - Polati, Enrico AU - Donadello, Katia AU - Friso, Simonetta AU - Pizzolo, Francesca AU - Iezzi, Manuela AU - Facciotti, Federica AU - Pelicci, Piergiuseppe AU - Righetti, Daniela AU - Bazzoni, Paolo AU - Rampudda, Mariaelisa AU - Comel, Andrea AU - Mosaner, Walter AU - Lunardi, Claudio AU - Olivieri, Oliviero TI - Baricitinib restrains the immune dysregulation in COVID-19 patients AID - 10.1101/2020.06.26.20135319 DP - 2020 Jan 01 TA - medRxiv PG - 2020.06.26.20135319 4099 - http://medrxiv.org/content/early/2020/06/29/2020.06.26.20135319.short 4100 - http://medrxiv.org/content/early/2020/06/29/2020.06.26.20135319.full AB - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the ongoing pandemic coronavirus disease 2019 (COVID-19). The majority of patients with COVID-19 have a good prognosis, but variable percentages in different countries develop pneumonia associated with lymphocytopenia and severe inflammatory response due to uncontrolled release of cytokines. These immune mediators are transcriptionally regulated by JAK-STAT molecular pathways, which can be disabled by small molecules. Here, we provide evidences on the efficacy of baricitinib, a JAK1/JAK2 inhibitor, in correcting the immune abnormalities observed in patients hospitalized with COVID-19. Indeed, we demonstrate a significant reduction in serum levels of interleukin (IL)-6, IL-1β and tumor necrosis factor (TNF)α, a rapid recovery in circulating T and B cell frequencies and an increased antibody production against SARS-CoV-2 spike protein in baricitinib-treated patients. Moreover, treated patients underwent a rapid reduction in oxygen flow need and progressive increase in the P/F. Our work provides the basis on developing effective treatments against COVID-19 pathogenesis using on-target therapy.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04438629Funding StatementThis work was supported by Fondazione Cariverona (ENACT Project) and Fondazione TIM.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:DA RIEMPIRE!!!!!All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe authors declare that all the other data supporting the findings of this study are available within the article and its supplementary information files and from the corresponding authors upon reasonable request.